Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic. The company was founded in 2019 and is based in New Taipei City, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Buy
Sell